Hyderabad: Bharat Biotech International Limited (BBIL), the city-based vaccine maker, on Thursday said that its BBV152, a whole-virion inactivated Covid-19 vaccine candidate for immunising those in the two- to 18-year-old age group, has proven to be safe, well-tolerated, and immunogenic.
The company said in its phase II/III multicentre studies in healthy children and adolescents, found no serious adverse events, with 374 subjects reporting either mild or moderate severity symptoms, with most getting resolved within one day. Pain at the injection site was the most commonly reported adverse event.
The company received an emergency use nod for its Covaxin for children from the Central Drugs Standard Control Organisation recently.
Dr Krishna Ella, Bharat Biotech chairman and managing director, said, “We have achieved our goal of developing a safe and efficacious Covid-19 vaccine for adults and children. Vaccines are a great preventive tool; the power of vaccines can only be harnessed if used prophylactically.”
